Income statement
CAD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -14M | -3M | -7M | -15M | -9M |
| EBITDA | -14M | -3M | -7M | -15M | 0 |
| Net Income | -12M | -3M | -7M | -15M | -9M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$65.79
+3.38% today
1Y Change
+132.32%
Window
Jun 30, 2025 → Jun 18, 2026
Coverage: 244 bars · Jun 30, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Bright Minds Biosciences Inc. (DRUG) is a Healthcare stock with a market cap of $890.00M and listed on NASDAQ. The stock last traded around $65.79 and up 132.3% across the available one-year price window (Jun 30, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -173.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -173.8%, free cash flow -369.8% with operating margin 0.0% and ROIC -21.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DRUG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
DRUG is 111.46 pts ahead over the shared 1Y window.
DRUG had 29.22 pts deeper max drawdown than SPY.
DRUG beat SPY in 1 of 2 calendar years shown and trailed in 1.
DRUG
+132.32%
Normalized return
SPY
+20.86%
S&P 500
Excess Return
+111.46 pts
Relative to SPY
DRUG Max Drawdown
-38.35%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for DRUG and SPY.
| Year | DRUG | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | -27.32% | +6.71% | -34.03 pts | SPY |
| 2025 | +190.50% | +11.19% | +179.31 pts | DRUG |
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$8.7M
+42.2% YoY
Free Cash Flow
-$7.3M
+46.1% YoY
Revenue Growth
+0.0%
EPS Growth
-173.8%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -14M | -3M | -7M | -15M | -9M |
| EBITDA | -14M | -3M | -7M | -15M | 0 |
| Net Income | -12M | -3M | -7M | -15M | -9M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 83M | 6M | 7M | 12M | 20M |
| Total Assets | 84M | 6M | 7M | 12M | 20M |
| Total Liabilities | 2M | 568K | 281K | 2M | 639K |
| Shareholder Equity | 82M | 6M | 7M | 11M | 19M |
| Total Debt | 126K | 119K | 74K | 140K | 0 |
| Net Debt | -83M | -6M | -7M | -11M | -20M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
7M
+46.1% YoY
Capital Expenditures
0
Free Cash Flow
7M
+46.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-28.5%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.